Are weight loss injections available on the NHS?

What NICE guidance actually says about NHS weight loss injections

The starting point is the official clinical evidence. NICE approved semaglutide (Wegovy) in March 2023 under technology appraisal TA875, recommending it for adults with a BMI of 35 or above plus at least one weight-related health condition, used for a maximum of two years within a specialist weight management service. Tirzepatide (Mounjaro) followed in December 2024 under TA1026, with a broader set of eligible comorbidities and no two-year time limit written into the recommendation. Both approvals came after large randomised trials demonstrated meaningful average weight reductions that NICE considered cost-effective for the NHS.

The BMI thresholds above drop by 2.5 kg/m² for adults from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK clinical guidance, so 32.5 instead of 35 for the upper band, for example. BMI alone is never the whole story; a clinician weighs up the broader picture before any prescription is written. You can check your current BMI using the NHS BMI calculator.

Which injections are currently available on the NHS, and for whom

The injection that has been more widely rolled out through NHS specialist services is Wegovy (semaglutide). Tirzepatide is newer to the NHS and subject to a phased commissioning schedule that NHS England began implementing from 2025.

For tirzepatide on the NHS, the phasing works like this. From June 2025, adults with a BMI of 40 or above plus four or more of five specified conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes) became eligible. A second cohort (BMI 35 to 39.9 with four or more of those conditions) opened in June 2026. Further cohorts with lower thresholds are scheduled for 2027 and beyond. From April 2026, GP practices can prescribe tirzepatide directly under the new GP contract, though participation varies by practice. Full detail on the NHS England weight management injections page is worth reading before you contact your surgery.

Wegovy sits separately: access has principally been through tier 3 and tier 4 specialist services, where waiting lists in many areas run to months or longer. If you want a clearer sense of whether the weight loss injection is available on the NHS right now, the picture differs meaningfully by where you live and which service your GP can refer you to.

What happens if you qualify but still face a wait, or don't qualify yet

Meeting the criteria on paper does not guarantee a swift appointment. Specialist weight management services are in high demand, and GP practices that have signed up to prescribe tirzepatide vary across England. Some patients find their practice is not yet participating; others meet most criteria but not all. If you are in that position and want to understand the private route, it helps to know what that actually involves before making any decisions. A read of how NHS weight loss injections compare to the private route is a practical next step.

Private prescription through a GPhC-registered online pharmacy is the legal alternative. It does not require a referral or a waiting list, but it does still require a genuine clinical assessment, a prescriber reviews your consultation personally. For anyone considering that path, understanding what private weight loss injection costs typically include is worth doing before committing, since headline prices can exclude consultation, prescription or aftercare. That matters more for a prescription medicine than it would for an over-the-counter product, because the clinical element is not optional.

One thing our prescribing team hears regularly: people who assumed they would qualify on the NHS and then found the current cohort thresholds placed them just outside. The phased rollout is real, and it will expand, but for many adults the timeline for NHS access is still uncertain.

Safety, monitoring and the NHS wraparound requirement

Both NICE recommendations carry a requirement for supervised lifestyle support alongside the medicine. For semaglutide under TA875, this means specialist multidisciplinary management. For tirzepatide under TA1026, NHS commissioning guidance specifies wraparound dietary and physical activity support as a condition of prescribing. The medicines are not handed over as a standalone fix; the clinical framework around them is part of what makes them effective and safe at scale.

On safety more broadly, these are well-studied medicines. The most common side effects are gastrointestinal (nausea, loose stools, constipation and indigestion feature prominently in the trial data) and they tend to ease after the first few weeks. The MHRA monitors both medicines under the Black Triangle scheme, meaning new safety information is actively collected and published. If you want a thorough look at the evidence on tolerability, our page examining whether weight loss injections are safe on the NHS covers this in more detail, and you can also find a broader overview of whether weight loss injections are safe according to NHS evidence if you want to compare sources before speaking to a clinician. Patients and clinicians can report suspected side effects directly via the MHRA Yellow Card scheme.

If your situation in Northern Ireland means NHS guidance feels distant or unclear, the position there differs from England and is worth checking separately.